A functional landscape of resistance to ALK inhibition in lung cancer.

[1]  Kate Owen,et al.  Author response: Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2015 .

[2]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[3]  C. Emery,et al.  Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations , 2014, Oncogene.

[4]  Michael R. Green,et al.  A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia , 2014, Science Translational Medicine.

[5]  Michael L. Gatza,et al.  An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer , 2014, Nature Genetics.

[6]  William Pao,et al.  Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer , 2014, Nature Medicine.

[7]  S. Yano,et al.  Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells , 2014, Oncotarget.

[8]  J. Mesirov,et al.  A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.

[9]  Makoto Nishio,et al.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.

[10]  I. Petersen,et al.  CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[11]  A. Shaw,et al.  Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer , 2013, Clinical pharmacology and therapeutics.

[12]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[13]  V. Trinkaus-Randall,et al.  Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation. , 2013, The American journal of pathology.

[14]  Rajiv Narayan,et al.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.

[15]  Jeffrey A. Engelman,et al.  Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.

[16]  A. Gesierich,et al.  Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives , 2013, Cancer medicine.

[17]  H. Hassan,et al.  Extracellular nucleotides inhibit oxalate transport by human intestinal Caco-2-BBe cells through PKC-δ activation. , 2013, American journal of physiology. Cell physiology.

[18]  B. Hille,et al.  Quantitative properties and receptor reserve of the IP3 and calcium branch of Gq-coupled receptor signaling , 2013, The Journal of general physiology.

[19]  B. Hille,et al.  Quantitative properties and receptor reserve of the DAG and PKC branch of Gq-coupled receptor signaling , 2013, The Journal of general physiology.

[20]  G. Inghirami,et al.  The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1 , 2013, Oncogenesis.

[21]  M. Hristova,et al.  ATP-Mediated Transactivation of the Epidermal Growth Factor Receptor in Airway Epithelial Cells Involves DUOX1-Dependent Oxidation of Src and ADAM17 , 2013, PloS one.

[22]  P. Pelegrín,et al.  The participation of plasma membrane hemichannels to purinergic signaling. , 2013, Biochimica et biophysica acta.

[23]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[24]  F. Di Virgilio,et al.  Purines, purinergic receptors, and cancer. , 2012, Cancer research.

[25]  Jeffrey A. Porter,et al.  Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. , 2012, Cancer discovery.

[26]  Kazuko Sakai,et al.  Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[27]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[28]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[29]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[30]  S. Peters,et al.  MET: a promising anticancer therapeutic target , 2012, Nature Reviews Clinical Oncology.

[31]  Shinji Takeuchi,et al.  Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells , 2012, Clinical Cancer Research.

[32]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[33]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[34]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[35]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[36]  William C Hahn,et al.  Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. , 2011, Cancer discovery.

[37]  Wei Zheng,et al.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.

[38]  Thomas M Green,et al.  A public genome-scale lentiviral expression library of human ORFs , 2011, Nature Methods.

[39]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[40]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[41]  M. Tsukimoto,et al.  P2Y6 Receptors and ADAM17 Mediate Low-Dose Gamma-Ray-Induced Focus Formation (Activation) of EGF Receptor , 2011, Radiation research.

[42]  A. Iafrate,et al.  Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[44]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[45]  W. G. Wood,et al.  P2Y2 Nucleotide Receptor-Mediated Responses in Brain Cells , 2010, Molecular Neurobiology.

[46]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[47]  S. Rikka,et al.  P2Y2 Nucleotide Receptors Mediate Metalloprotease-dependent Phosphorylation of Epidermal Growth Factor Receptor and ErbB3 in Human Salivary Gland Cells , 2010, The Journal of Biological Chemistry.

[48]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[49]  J. Huidobro-Toro,et al.  Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells , 2007, Journal of Cell Science.

[50]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[51]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[52]  A. Chinnaiyan,et al.  Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.

[53]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Tobias Welte,et al.  ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. , 2003, American journal of physiology. Lung cellular and molecular physiology.